Important note: Information in this article was accurate in August 2007. The state of the art may have changed since the publication date.
HIV Treatment Bulletin - Vol. 8, No. 8/9, August-September 2007
Simon Collins, HIV i-Base
Francois Raffi from University Hospital, Nantes, France, presented interim results (24 week) from the Gemini study, which randomised 337 treatment-naïve patients to twice daily regimen of SQV/r (1000mg/100mg BID) or standard dose lopinavir/r BID.[1]
Baseline viral load and CD4 count were balanced between each arm (approximate median (range) of 5.2 logs (4.0–7.0) and 137 cells/mm3 (1–580) respectively). Baseline viral load was >100,000 copies/mL in 67% - 63% patients.
Virological responseswere similarwith 89% and 69% patients ineach arm suppressed to<400and <50copies/mLrespectively. Virological failure occurred more frequently in the saquinavir arm (10/166, 6% vs 3/171, 1.8%) and new PI resistance was only reported in two patients in the saquinavir arm.
Lipid data, presented in a poster from Sharon Walmsley, showed that total cholesterol, LDL and HDL all increased by a similar amount in the SQV/r and LPV/r arms (by approximately +180, +100 and +45mg/dL respectively), with triglycerides increasing slightly less in the saquinavir arm (+129 vs +161 mg/dL).[2]
A higher percentage of patients using lopinavir/r had lipid changes that left them over NCEP guidelines for using lipid lowering drugs (1.2 vs 8.9% for cholesterol and 21.5 vs 26.8% for triglycerides).
As with previous presentations of this study, 48-week results are needed to know the clinical importance of these differences in a head-to-head study.
References
| 1. | Raffi F, Ward D, Ruxrungtham K et al. Saquinavir/r (SQV/r) BID vs lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD as initial therapy in HIV-1 infected patients: the Gemini Study. IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th: (Abstract No. WEPEB027). |
| 2. | Walmsley S, Bredeek U, Avihingsanon A et al. Evaluation of the impact of highly active antiretroviral therapy (HAART) on lipid profiles – data from the 24-week interim analysis of the Gemini Study: saquinavir/r (SQV/r) BID vs lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/ TDF) QD in ARV-naïve HIV-1-infected patients. IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th: (Abstract No. TUPEB069). |
2007-08-10
IB070808-12
©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.